Biotech
China Pharma to Launch Highly Purified NMN+PQQ Product
2021-06-09 20:00
9477
HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...
Hummingbird Bioscience and Novogene enter into strategic partnership to expand precision medicine testing for individuals with NRG1-fusion driven cancers in China
2021-06-09 17:00
1502
HOUSTON and SINGAPORE, June 9, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company, Novoge...
Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer
2021-06-09 13:38
1648
SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd. incorporated inSingapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S....
Innoforce Pharmaceuticals to Participate in BIO International Digital Convention
2021-06-08 19:00
1761
HANGZHOU, China and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("Innoforce"), an innovation and partnership-focused biopharmaceutical company, today announces that the company is participating in the BIO International Digital Convention (BIO Digital) being held fromJun...
TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
2021-06-08 16:53
2209
LONGJUMEAU, France, June 8, 2021 /PRNewswire/ -- The French biotech TargEDys specialized in breakthrough microbiome-based solutions announces the publication of its study conducted in 230 overweight adults supplemented for 12 weeks, confirming the efficacy of the precision probioticHafnia alvei H...
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL
2021-06-08 07:30
4434
SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first...
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
2021-06-08 07:21
11147
SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at t...
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication
2021-06-07 08:30
2674
HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries
2021-06-07 08:00
1877
ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
2021-06-04 02:00
1898
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...
RWDC Industries Appoints New Chief Financial Officer
2021-06-03 22:00
2060
Thomas Aebischer brings 18 years of public and private company CFO experience and proven leadership track record to RWDC ATHENS, Georgia and SINGAPORE, June 3, 2021 /PRNewswire/ -- RWDC Industries, a biotechnology company on a mission to replace single-use plastics through innovative and cost-ef...
Peking University Biologics entering into Strategic Cooperation Agreement with Norwich Investment Limited
2021-06-03 16:29
2644
HONG KONG, June 3, 2021 /PRNewswire/ -- Peking University Biologics (hereinafter known as "PKU BIO") and Norwich Investment Limited (hereinafter known as "Norwich") announced today that both parties have entered into a Strategic Cooperation Agreement ("Agreement") to promote the business develop...
Cell Care Joins the Generate Life Sciences Family to Create a Global Platform
2021-06-03 06:00
1931
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell banking and research MELBOURNE, Australia, June 3, 2021 /PRNewswire/ -- Cell Care, Australia's leading cord blood bank, today announced it has be...
Nanoform raises its mid-term business targets for 2025
2021-06-02 21:42
1409
HELSINKI, June 2, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows: * To nanoform annually at least 70 new active pharmaceutical ...
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
2021-06-02 21:00
8672
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
2021-06-02 20:10
1396
SUZHOU, China, June 2, 2021 /PRNewswire/ -- On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI).Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with i...
PharmAbcine to Present at the BIO Digital International Convention 2021
2021-06-02 20:00
2099
DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...
Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd
2021-06-02 16:23
1261
STOCKHOLM, June 2, 2021 /PRNewswire/ -- Betagenon AB, a Sweden-based biotech company focused on development of AMPK activator compounds, and MCG Technology Group Ltd, aHong Kong-based biotech investment group, today announced that MCG Technology Group will invest in and collaborate with Betagenon...
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
2021-06-02 16:14
1092
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from
its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at
the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-
8, 2021 for the first time.
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
2021-06-02 06:00
1359
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00Most Read
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
2892